OncoMatch/Clinical Trials/NCT06828354
A Study of SHR-A1811 in Subjects With Ovarian Cancer
Is NCT06828354 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments for ovarian cancer.
Treatment: SHR-A1811 · Paclitaxel · Doxorubicin Hydrochloride Liposome · Gemcitabine Hydrochloride for · Topotecan Hydrochloride for — This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Ovarian Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06828354 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages